Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion

1-Year follow-up

Alfredo Pece, Vincenzo Isola, Stefano Piermarocchi, Giliola Calori

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab (Lucentis) in patients with treatment-naive retinal vein occlusion. Design: Prospective, consecutive, non-comparative, interventional case series. Participants: Seventeen eyes of 17 consecutive patients with naive retinal vein occlusion. Methods: Consecutive patients were recruited and received, on demand, intravitreal 0.5 mg of ranibizumab; nine had central retinal vein occlusion (CRVO) and eight had branch retinal vein occlusion (BRVO). Pre- and postoperative clinical evaluation included measurement of best corrected visual acuity (BCVA) for distance, and near vision (MNREAD time, reading fluency), contrast sensitivity, colour fundus photography, fluorescein angiography and optical coherence tomography (OCT). All subjects were followed for a minimum of 12 months. Main outcome measures: Change in BCVA, contrast sensitivity, angiographic leakage, OCT central macular thickness (CMT), number of treatments. Results: Patients with CRVO had mean pre-treatment BCVA of 20/240 (1.08±0.25 logarithm of the minimum angle of resolution (logMAR)) and final BCVA of 20/46 (0.36±0.16 logMAR), with significant improvement at 1 year of follow-up (p

Original languageEnglish
Pages (from-to)56-68
Number of pages13
JournalBritish Journal of Ophthalmology
Volume95
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Retinal Vein Occlusion
Vascular Endothelial Growth Factor A
Visual Acuity
Safety
Retinal Vein
Contrast Sensitivity
Optical Coherence Tomography
Therapeutics
Fluorescein Angiography
Photography
Reading
Color
Outcome Assessment (Health Care)
Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Cellular and Molecular Neuroscience
  • Sensory Systems

Cite this

Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion : 1-Year follow-up. / Pece, Alfredo; Isola, Vincenzo; Piermarocchi, Stefano; Calori, Giliola.

In: British Journal of Ophthalmology, Vol. 95, No. 1, 01.2011, p. 56-68.

Research output: Contribution to journalArticle

@article{45637b159cd2419ba310d037d031689a,
title = "Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-Year follow-up",
abstract = "Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab (Lucentis) in patients with treatment-naive retinal vein occlusion. Design: Prospective, consecutive, non-comparative, interventional case series. Participants: Seventeen eyes of 17 consecutive patients with naive retinal vein occlusion. Methods: Consecutive patients were recruited and received, on demand, intravitreal 0.5 mg of ranibizumab; nine had central retinal vein occlusion (CRVO) and eight had branch retinal vein occlusion (BRVO). Pre- and postoperative clinical evaluation included measurement of best corrected visual acuity (BCVA) for distance, and near vision (MNREAD time, reading fluency), contrast sensitivity, colour fundus photography, fluorescein angiography and optical coherence tomography (OCT). All subjects were followed for a minimum of 12 months. Main outcome measures: Change in BCVA, contrast sensitivity, angiographic leakage, OCT central macular thickness (CMT), number of treatments. Results: Patients with CRVO had mean pre-treatment BCVA of 20/240 (1.08±0.25 logarithm of the minimum angle of resolution (logMAR)) and final BCVA of 20/46 (0.36±0.16 logMAR), with significant improvement at 1 year of follow-up (p",
author = "Alfredo Pece and Vincenzo Isola and Stefano Piermarocchi and Giliola Calori",
year = "2011",
month = "1",
doi = "10.1136/bjo.2009.174060",
language = "English",
volume = "95",
pages = "56--68",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion

T2 - 1-Year follow-up

AU - Pece, Alfredo

AU - Isola, Vincenzo

AU - Piermarocchi, Stefano

AU - Calori, Giliola

PY - 2011/1

Y1 - 2011/1

N2 - Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab (Lucentis) in patients with treatment-naive retinal vein occlusion. Design: Prospective, consecutive, non-comparative, interventional case series. Participants: Seventeen eyes of 17 consecutive patients with naive retinal vein occlusion. Methods: Consecutive patients were recruited and received, on demand, intravitreal 0.5 mg of ranibizumab; nine had central retinal vein occlusion (CRVO) and eight had branch retinal vein occlusion (BRVO). Pre- and postoperative clinical evaluation included measurement of best corrected visual acuity (BCVA) for distance, and near vision (MNREAD time, reading fluency), contrast sensitivity, colour fundus photography, fluorescein angiography and optical coherence tomography (OCT). All subjects were followed for a minimum of 12 months. Main outcome measures: Change in BCVA, contrast sensitivity, angiographic leakage, OCT central macular thickness (CMT), number of treatments. Results: Patients with CRVO had mean pre-treatment BCVA of 20/240 (1.08±0.25 logarithm of the minimum angle of resolution (logMAR)) and final BCVA of 20/46 (0.36±0.16 logMAR), with significant improvement at 1 year of follow-up (p

AB - Purpose: To evaluate the efficacy and safety of intravitreal ranibizumab (Lucentis) in patients with treatment-naive retinal vein occlusion. Design: Prospective, consecutive, non-comparative, interventional case series. Participants: Seventeen eyes of 17 consecutive patients with naive retinal vein occlusion. Methods: Consecutive patients were recruited and received, on demand, intravitreal 0.5 mg of ranibizumab; nine had central retinal vein occlusion (CRVO) and eight had branch retinal vein occlusion (BRVO). Pre- and postoperative clinical evaluation included measurement of best corrected visual acuity (BCVA) for distance, and near vision (MNREAD time, reading fluency), contrast sensitivity, colour fundus photography, fluorescein angiography and optical coherence tomography (OCT). All subjects were followed for a minimum of 12 months. Main outcome measures: Change in BCVA, contrast sensitivity, angiographic leakage, OCT central macular thickness (CMT), number of treatments. Results: Patients with CRVO had mean pre-treatment BCVA of 20/240 (1.08±0.25 logarithm of the minimum angle of resolution (logMAR)) and final BCVA of 20/46 (0.36±0.16 logMAR), with significant improvement at 1 year of follow-up (p

UR - http://www.scopus.com/inward/record.url?scp=78650824570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650824570&partnerID=8YFLogxK

U2 - 10.1136/bjo.2009.174060

DO - 10.1136/bjo.2009.174060

M3 - Article

VL - 95

SP - 56

EP - 68

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 1

ER -